Use of Anti-IL-6 Biologics in Rheumatoid Arthritis Patients in Wales
Author Information
Author(s): Roxanne Cooksey, Jonathan Kennedy, Muhammad Rahman, Sinead Brophy, Ernest Choy
Primary Institution: Cardiff University
Hypothesis
What factors are associated with the initiation and discontinuation of anti-IL-6 biologic DMARDs compared to non-anti-IL-6 biologics in rheumatoid arthritis patients?
Conclusion
Patients treated with anti-IL-6 biologics were more likely to continue treatment than those treated with non-anti-IL-6 biologics.
Supporting Evidence
- 95.7% of patients received conventional synthetic DMARDs.
- 36.2% of patients were treated with biologic DMARDs.
- 6.5% of biologic-naïve patients were treated with anti-IL-6 bDMARDs.
- Treatment discontinuation was higher in non-anti-IL-6 bDMARD-treated patients.
Takeaway
This study looked at how different medicines help people with arthritis and found that some medicines work better for keeping patients on treatment.
Methodology
A retrospective cohort study using electronic health records from the Secure Anonymised Information Linkage Databank.
Potential Biases
Potential underpowering to detect associations due to low numbers of patients on anti-IL-6 bDMARDs.
Limitations
The cohort may not represent early or less severe rheumatoid arthritis patients, and the absence of certain clinical data may limit findings.
Participant Demographics
Mean age of 62 years, 71.6% female, mean disease duration of 6.3 years.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 1.1, 17.8
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website